Insider Buying: BCAL Diagnostics (ASX:BDX) Insider Buys 192,000 Shares of Stock

BCAL Diagnostics Limited (ASX:BDX) insider Jayne Shaw purchased 192,000 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was acquired at an average price of A$0.12 per share, for a total transaction of A$23,616.00.

BCAL Diagnostics Stock Performance

The company has a debt-to-equity ratio of 17.74, a quick ratio of 6.70 and a current ratio of 3.60. The stock has a market cap of $36.60 million, a PE ratio of -4.08 and a beta of 0.69.

About BCAL Diagnostics

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.